USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: ETUBICS CORPORATION
Address: 9715 FREMONT AVE N
SEATTLE, WA 98103-3140
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,221,335.00 5
SBIR Phase II $7,323,103.00 3

Award List:

Improved HIV-Adenoviral Vector Vaccine for Re-immunization

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard B. Gayle
Award Amount: $621,380.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to develop an adenoviral vector vaccine against HIV that is effective in stimulating cell-mediated immunity in animals previously immune to adenovirus The HIV vaccine will be used to protect against infection and to treat the… More

Development of a Novel CEA Expressing Adenovirus for Treatment

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $112,995.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to continue developing an adenoviral vector vaccine against CEA that is effective in stimulating cell-mediated immunity in animals previously immune to adenovirus. The Ad-CEA vaccine en dpoint is to treat patients with CEA… More

Development of a Novel Her2/neu Expressing Adenovirus for Treatment

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Frank R. Jones
Award Amount: $123,567.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to continue developing an adenoviral serotype 5 (Ad5) vector vaccine against Ad5[E1-, E2b]-Her2/neu that is effective in stimulating cell-mediated immunity (CMI) in animals previously i mmune to Ad5. The Ad5[E1-, E2b-]- Her2/neu… More

Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Frank R. Jones
Award Amount: $3,353,817.00
Abstract:
DESCRIPTION (provided by applicant): Current generation Adenovirus (Ad) vector vaccines deleted at the E1 or the E1, E3 regions have resulted in experimental potential to immunize against a variety of infectious diseases such as HIV. These Ad vectors permi t the delivery of genes, which express… More

Development of a Novel CEA Expressing Ad5 [E1-, E2b-] Vector for Treatment

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Frank R. Jones
Award Amount: $2,470,285.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to continue to develop an adenoviral vector vaccine against CEA that is effective in stimulating cell-mediated immune responses in subjects previously immune to Adenovirus. The Ad-CEA v accine endpoint is to treat patients with… More

Therapeutic Vaccine for HIV/HPV-associated Oropharyngeal and Tonsillar Malignanci

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Frank R. Jones – 206-838-5110
Award Amount: $163,405.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to develop a therapeutic strategy for H V-associated malignancy based on the role of HPV in the pathogenesis. HPV related cancers express the E6/E7 oncoproteins of HPV that are ideal targets for immune inducing vaccines. We will… More

TAS::75 0849::TAS TOPIC 255 CGMP MANUFACTURE OF A NOVEL HER2/NEU EXPRESSING ADENOVIRUS FOR TREATMENT

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph Balint – 206-838-5110
Award Amount: $199,988.00
Abstract:
This Phase I, SBIR contract is for the development of a new vaccine targeting HER2/neu expressing breast cancers. The vaccine induces both cell-mediated and humoral immunity and the company is planning a first-in-man Phase I/Phase II clinical trial. It isanticipated that this new biotherapeutic… More

TAS::75 0849 - TOPIC 255 PHASE II, CGMP MANUFACTURE OF A NOVEL CEA EXPRESSING AD5 VIRUS

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Frank Jones – 206-838-5110
Award Amount: $1,499,001.00
Abstract:
Etubics Corporation is clinically testing a new vaccine targeting carcinoembryonic antigen (CEA) expressing cancers in a Phase I/II clinical trials under FDA IND14325. Many cancers express CEA, including colon, breast and pancreatic cancers. It is anticipated that this new biotherapeutic product… More